.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Merck
Express Scripts
US Department of Justice
Mallinckrodt
Medtronic
Argus Health
QuintilesIMS
Cipla

Generated: September 21, 2017

DrugPatentWatch Database Preview

Enzalutamide - Generic Drug Details

« Back to Dashboard

What are the generic sources for enzalutamide and what is the scope of enzalutamide freedom to operate?

Enzalutamide
is the generic ingredient in one branded drug marketed by Astellas and is included in one NDA. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Enzalutamide has ninety-five patent family members in twenty-five countries.

There are nine drug master file entries for enzalutamide. One supplier is listed for this compound.

Summary for Generic Name: enzalutamide

Tradenames:1
Patents:3
Applicants:1
NDAs:1
Drug Master File Entries: see list9
Suppliers / Packagers: see list1
Bulk Api Vendors: see list69
Clinical Trials: see list178
Patent Applications: see list153
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:enzalutamide at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas
XTANDI
enzalutamide
CAPSULE;ORAL203415-001Aug 31, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Astellas
XTANDI
enzalutamide
CAPSULE;ORAL203415-001Aug 31, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Astellas
XTANDI
enzalutamide
CAPSULE;ORAL203415-001Aug 31, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Astellas
XTANDI
enzalutamide
CAPSULE;ORAL203415-001Aug 31, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Astellas
XTANDI
enzalutamide
CAPSULE;ORAL203415-001Aug 31, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: enzalutamide

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,110,594Diarylthiohydantoin compounds► Subscribe
8,648,105Diarylthiohydantoin compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: enzalutamide

Country Document Number Estimated Expiration
New Zealand710355► Subscribe
South Korea101431407► Subscribe
Norway339997► Subscribe
South Korea101332924► Subscribe
Hong Kong1124612► Subscribe
Japan5350217► Subscribe
South Korea20150008506► Subscribe
Israel243812► Subscribe
Japan5138753► Subscribe
Israel187328► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ENZALUTAMIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90060-0Sweden► SubscribePRODUCT NAME: ENZALUTAMID OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV; REG. NO/DATE: EU/1/13/846 20130621
1Finland► Subscribe
2013 00065Denmark► SubscribePRODUCT NAME: ENZALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/846 20130625
2013029,C1893196Lithuania► SubscribePRODUCT NAME: ENZALUTAMIDUM; REGISTRATION NO/DATE: EU/1/13/846 20130625
13/061Ireland► SubscribePRODUCT NAME: ENZALUTAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/846 20130625
2013 00065Denmark► SubscribePRODUCT NAME: ENZALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/846 20130625
0130036 00106Estonia► SubscribePRODUCT NAME: ENSALUTAMIID;REG NO/DATE: K(2013)4019 (LOPLIK) 25.06.2013
C0071France► SubscribePRODUCT NAME: ENZALUTAMIDE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/846 20130625
9 50005-2013Slovakia► SubscribePRODUCT NAME: ENZALUTAMID; REGISTRATION NO/DATE: EU/1/13/846 20130621
2013000155Germany► SubscribePRODUCT NAME: ENZALUTAMID ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ HIERVON; REGISTRATION NO/DATE: EU/1/13/846 20130621
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Dow
Citi
UBS
Federal Trade Commission
Argus Health
Queensland Health
Cerilliant
Johnson and Johnson
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot